Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this space.
A couple of products obtained through acquisitions and licensing deals have already been commercialized in the country and the firm...







